Table 2 Univariate and multivariate analyses for breast cancer-specific survival

A. Hormone receptor-positive

Pathological stage

.001

.001

 Stage I

1.00

1.00

 Stage II

2.81 (1.82–4.34)

1.81 (0.87–3.76)

 Stage III

14.34 (9.50–21.67)

5.99 (2.34–15.34)

Tumor size: > 5 vs. ≤ 5 cm

6.82 (4.81–9.68)

.001

1.59 (0.83–3.03)

.159

LNR: Above vs. Below mean

4.10 (3.07–5.47)

.001

1.24 (0.64–2.38)

.527

Histological grade: G3 vs. G1/2

4.20 (3.14–5.60)

.001

3.41 (2.04–5.69)

.001

Lymphatic invasion: Yes vs. No

3.28 (2.44–4.41)

.001

1.65 (0.94–2.89)

.079

Vascular invasion: Yes vs. No

2.70 (1.94–3.75)

.001

0.79 (0.42–1.49)

.471

Ki-67: < 14 vs. ≥ 14%

0.54 (0.34–0.84)

.006

0.95 (0.57–1.56)

.825

HER2: Low vs. IHC 0

0.61 (0.44–0.85)

.003

0.72 (0.44–1.17)

.186

B. Hormone receptor-negative

Pathological stage

.001

.001

 Stage I

1.00

1.00

 Stage II

2.80 (1.89–4.14)

2.03 (1.35–3.05)

 Stage III

12.95 (8.77–19.13)

3.95 (2.34–6.63)

Tumor size: > 5 vs. ≤ 5 cm

5.38 (3.97–7.29)

.001

1.94 (1.38–2.74)

.001

LNR: Above vs. Below mean

4.89 (3.83–6.26)

.001

1.92 (1.37–2.67)

.001

Histological grade: G3 vs. G1/2

1.29 (0.95–1.73)

.102

Lymphatic invasion: Yes vs. No

4.27 (3.29–5.53)

.001

1.74 (1.23–2.46)

.006

Vascular invasion: Yes vs. No

3.88 (2.96–5.09)

.001

1.38 (0.99–0.19)

.132

Ki-67: < 14 vs. ≥ 14%

0.90 (0.54–1.49)

.691

HER2: Low vs. IHC 0

0.69 (0.50–0.95)

.023

0.68 (0.49–0.93)

.019